alexa Early Breast Cancer Detection With Bi-modal Molecular Imaging
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

5th World Congress on Biotechnology
June 25-27, 2014 Valencia Conference Centre, Valencia, Spain

Barbara Blasiak
ScientificTracks Abstracts: J Biotechnol Biomater
DOI: 10.4172/2155-952X.S1.027
Breast cancer is the most frequently diagnosed cancer in women. Currently mammography is the main screening and diagnostic tool, however it exposes the patient to radiation and its ability to distinguish benign and malignant disease are limited which results in a large number of unnecessary biopsies. PET provides information based on a tumor?s increased glucose consumption but doesn?t detect small tumors. Ultrasound allows differentiation between cystic and solid lesions with sharp borders, but doesn?t provide good differentiation between malignant and benign tumors.MRI has excellent spatial resolution but has not been applied to its full potential for the diagnosis of breast cancer due to its low specificity. At the same a combined PET/MRI human system has been introduced to clinics. Therefore a novel contrast agent for simultaneous PET and MR imaging that is specific to the most aggressive form of invasive ductal carcinoma (triple negative (TN)) is proposed. The bi-modal PET and MRI contrast agent enables both PET-MRI detection of this malignant breast cancer with high sensitivity (PET) and high spatial resolution (MRI). The development of a novel targeted contrast agent for breast molecular PET and MR imaging will considerably increase sensitivity of these imaging technologies enabling significant improvement in diagnosis. The specific aim of the study is to construct superparamagnetic core/shell nanoparticles that strongly reduce both T1 and T2 relaxation times. They will be conjugated with single domain antibodies (sdAbs) against three tumor targets overexpressed by the targeted breast cancer, creating very specific and efficient contrast agents.
Barbara Blasiak completed her PhD at the Institute of Nuclear Physics, Polish Academy of Sciences, Krakow, Poland. Her PhD thesis was on molecular imaging of glioma. Currently she is involved in applications of nano-technology in medicine at the University of Calgary, Canada. She has been a coordinator of the multi- site, cross-Canada project on molecular imaging. She continues her work on innovative rf coils for low and high field MRI systems. Blasiak is a recipient of several awards. She is an author of 12 publications related to molecular imaging of cancer.
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version